PeptideScanner retained ClinicalTrials.gov record NCT00811395 at 2026-11-16T17:42:50.457Z. Its registry update date was 2012-12-31, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT00097747 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide.
PeptideScanner retained ClinicalTrials.gov record NCT00228436 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide.
PeptideScanner retained ClinicalTrials.gov record NCT00228449 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide.
PeptideScanner retained ClinicalTrials.gov record NCT00272662 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide.
PeptideScanner retained ClinicalTrials.gov record NCT00252187 at 2026-11-16T01:39:41.882Z. Its registry update date was 2012-12-20, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT00295750 at 2026-11-15T21:52:09.579Z. Its registry update date was 2012-12-19, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT00426751 at 2026-11-15T21:59:29.646Z. Its registry update date was 2012-11-27, and PeptideScanner's reviewed identity mapping was eptifibatide.
PeptideScanner retained ClinicalTrials.gov record NCT00426153 at 2026-07-30T22:14:20.912Z. Its registry update date was 2012-11-21, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT01446783 at 2026-11-16T17:35:13.282Z. Its registry update date was 2012-11-20, and PeptideScanner's reviewed identity mapping was mecasermin.
PeptideScanner retained ClinicalTrials.gov record NCT00906347 at 2026-11-16T00:59:19.138Z. Its registry update date was 2012-11-15, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT00475865 at 2026-11-16T17:42:50.457Z. Its registry update date was 2012-11-06, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT01695109 at 2026-07-30T22:14:20.912Z. Its registry update date was 2012-09-27, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00605267 at 2026-11-15T21:50:32.222Z. Its registry update date was 2012-09-06, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT00752791 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-08-15, and PeptideScanner's reviewed identity mapping was peginesatide.
PeptideScanner retained ClinicalTrials.gov record NCT00667758 at 2026-11-15T22:02:39.332Z. Its registry update date was 2012-08-06, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT00752609 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-07-27, and PeptideScanner's reviewed identity mapping was peginesatide.
PeptideScanner retained ClinicalTrials.gov record NCT01184872 at 2026-11-15T22:01:45.056Z. Its registry update date was 2012-07-13, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT01637454 at 2026-11-15T21:47:40.408Z. Its registry update date was 2012-07-11, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT00003026 at 2026-11-15T21:49:16.513Z. Its registry update date was 2012-07-02, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT00434330 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-06-29, and PeptideScanner's reviewed identity mapping was peginesatide.
PeptideScanner retained ClinicalTrials.gov record NCT00680043 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-06-29, and PeptideScanner's reviewed identity mapping was peginesatide.
PeptideScanner retained ClinicalTrials.gov record NCT01078805 at 2026-07-30T22:14:20.917Z. Its registry update date was 2012-06-26, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT00666224 at 2026-11-16T17:42:50.457Z. Its registry update date was 2012-06-25, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT01056549 at 2026-07-30T22:14:20.917Z. Its registry update date was 2012-06-22, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00004895 at 2026-07-30T22:14:20.917Z. Its registry update date was 2012-06-06, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT00334022 at 2026-11-16T01:41:15.051Z. Its registry update date was 2012-06-05, and PeptideScanner's reviewed identity mapping was enfuvirtide.
PeptideScanner retained ClinicalTrials.gov record NCT01184859 at 2026-11-16T01:33:21.554Z. Its registry update date was 2012-05-25, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00387621 at 2026-11-16T01:39:41.882Z. Its registry update date was 2012-05-17, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT00373451 at 2026-11-15T21:58:19.888Z. Its registry update date was 2012-05-08, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT01028768 at 2026-11-15T21:55:23.600Z. Its registry update date was 2012-05-07, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01028924 at 2026-11-15T21:55:23.600Z. Its registry update date was 2012-05-07, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01588093 at 2026-11-16T17:35:13.282Z. Its registry update date was 2012-04-30, and PeptideScanner's reviewed identity mapping was mecasermin.
PeptideScanner retained ClinicalTrials.gov record NCT00171613 at 2026-07-30T22:14:20.909Z. Its registry update date was 2012-04-30, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT01580514 at 2026-07-30T22:14:20.913Z. Its registry update date was 2012-04-19, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT01080963 at 2026-11-15T22:01:45.056Z. Its registry update date was 2012-04-17, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT01031966 at 2026-11-15T22:10:40.222Z. Its registry update date was 2012-03-29, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.
PeptideScanner retained ClinicalTrials.gov record NCT00653757 at 2026-07-30T22:14:20.913Z. Its registry update date was 2012-03-19, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT01373606 at 2026-11-15T21:47:40.408Z. Its registry update date was 2012-02-14, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT00257426 at 2026-07-30T22:14:20.913Z. Its registry update date was 2012-02-14, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT00805935 at 2026-07-30T22:14:20.915Z. Its registry update date was 2012-01-27, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00079586 at 2026-11-15T21:58:19.888Z. Its registry update date was 2012-01-05, and PeptideScanner's reviewed identity mapping was bivalirudin.